Iron Sucrose: Clinical Guide
Primary Indications
Iron sucrose is indicated for treatment of iron deficiency anemia (IDA) in patients with chronic kidney disease (CKD), inflammatory bowel disease (IBD), and other conditions where oral iron is ineffective or not tolerated. 1
Specific Patient Populations:
- CKD patients (dialysis-dependent and non-dialysis-dependent) receiving erythropoietin therapy 1
- IBD patients with clinically active disease, prior oral iron intolerance, hemoglobin <10 g/dL, or requiring erythropoiesis-stimulating agents 1
- Patients intolerant to oral iron or with inadequate response to oral supplementation 1
- Hemodialysis patients as first-line therapy over oral iron 1
Dosing Regimen
Maximum Single Dose
The maximum single dose is 200 mg of elemental iron per the FDA label, though higher doses have been studied 1, 2.
Standard Dosing Protocols:
For CKD/Dialysis Patients:
- 100-200 mg per dialysis session (typically 3 times weekly) 1
- Maximum weekly dose: 500 mg 1
- Maintenance dosing: 100 mg monthly has shown efficacy in peritoneal dialysis patients 3
For IBD Patients:
- 200-300 mg per treatment episode, repeated as needed 1
- Total iron deficit can be estimated using simplified dosing schemes rather than Ganzoni formula 1
For General IDA:
- 200 mg twice weekly until iron stores replenished 4, 5
- Typical course: 5-10 doses total (1000-2000 mg cumulative) 1, 6
Pediatric Dosing:
- Weight-based dosing for children ≥2 years: 0.5-2 mg/kg 2
- Not established for children <2 years, though case series suggest safety at standard doses 7
Administration Methods
FDA-Approved Routes:
Intravenous bolus injection (preferred for convenience):
- 200 mg over 2-5 minutes as slow IV push 1, 2, 8
- Can be administered undiluted directly into dialysis line 8
- No test dose required (unlike iron dextran) 1, 9, 10
Intravenous infusion:
- 200 mg diluted in 100 mL normal saline over 15 minutes (FDA) 1, 2
- 200 mg over 30 minutes (EMA) 1
- 300 mg diluted in normal saline over 2 hours for higher doses 4
Critical Administration Notes:
- Doses >300 mg are NOT recommended due to increased hypotension and adverse reactions 4
- Resuscitation facilities must be available during administration 1
- The 2-minute push method results in considerable time and cost savings with acceptable safety profile 8
Monitoring Parameters
Before Treatment:
During Administration:
- Monitor for first 5 minutes for acute reactions 1, 8
- Vital signs, particularly blood pressure 4, 8
- Watch for metallic taste (occurs in ~18% of patients, benign) 8
Post-Treatment Monitoring:
Short-term (within 4 weeks):
- Hemoglobin should increase ≥2 g/dL within 4 weeks as acceptable response 1
- Peak hemoglobin typically occurs at 4-6 weeks post-treatment 6, 7
Laboratory reassessment:
- Transferrin and ferritin levels reliable 48 hours after administration 9
- For CKD patients on erythropoietin: Monitor TSAT and ferritin every 3 months 1
- Target ferritin >100 μg/L and TSAT 20-50% 1
Upper safety limits:
- Stop therapy if ferritin >800 μg/L or TSAT >50% to avoid iron overload 1
Long-term Follow-up:
- Hemoglobin and red cell indices every 3 months for 1 year, then annually 1
Contraindications and Precautions
Absolute Contraindications:
- Known hypersensitivity to iron sucrose or any component 2
- Evidence of iron overload (ferritin >800 μg/L, TSAT >50%) 1
Relative Contraindications/Cautions:
- Active infection - defer treatment until resolved 1
- Acute or chronic liver disease - use with caution 2
- First trimester pregnancy - insufficient safety data, though second/third trimester use appears safe 2
Special Populations:
Pregnancy:
- Can be used after first trimester with no reported adverse fetal outcomes 2
- Risk of severe hypersensitivity reactions may cause fetal bradycardia 2
Breastfeeding:
- Compatible with breastfeeding - no adverse effects in infants reported 2
- Monitor breastfed infants for gastrointestinal symptoms 2
Geriatric patients:
- No dose adjustment needed - 40% of post-marketing study patients were ≥65 years 2
Adverse Reactions and Management
Common Adverse Events (Non-serious):
- Metallic taste (17.9%) - transient, requires no intervention 8
- Injection site pain during or after administration 8
- Hypotension, nausea - typically mild and self-limited 1, 4
Serious Adverse Reactions:
Anaphylactoid reactions:
- Incidence: <1% with iron sucrose (significantly lower than iron dextran) 1, 9, 10
- No black box warning (unlike iron dextran) 1, 9
- Symptoms: hypotension, dizziness, nausea, circulatory collapse 1, 2
- All reactions resolve within 30 minutes with supportive care 8
Management of acute reactions:
- Stop infusion immediately 1
- Administer antihistamines, corticosteroids, epinephrine as needed 1
- No hospitalization typically required 8
Dose-Related Toxicity:
- Doses >300 mg associated with unacceptable reaction rates (36% at 500 mg dose) 4
- Symptoms include dizziness, hypotension, nausea, lower back pain 4
Safety in Iron Dextran-Sensitive Patients:
- Iron sucrose is safe in patients with documented iron dextran sensitivity 10
- No test dose required even in previously sensitive patients 10
Efficacy Outcomes
Hematologic Response:
- Mean hemoglobin increase: 1.9 g/dL within 4-6 weeks 5, 7
- Ferritin increases from ~10 ng/mL to >200 ng/mL after treatment course 6, 5
- 54% of patients achieve hemoglobin >11 g/dL vs 31% with oral iron 6
Comparative Effectiveness:
- Superior to oral iron for increasing ferritin and hemoglobin in CKD patients 6
- Equivalent efficacy to other IV iron formulations (ferric carboxymaltose, iron dextran) at 12 weeks 1
- Faster initial hemoglobin rise than oral iron, though 12-week outcomes similar 1
Erythropoietin-Sparing Effect:
- Reduces or eliminates erythropoietin requirements in many patients 6, 3
- Particularly beneficial in patients with baseline ferritin <100 ng/mL 6
Practical Considerations
Advantages Over Other Formulations:
- No test dose required (major advantage over iron dextran) 1, 9, 10
- Can be given as 2-minute push - significant time/cost savings 8
- Lower anaphylaxis risk than iron dextran 1, 9
- Decades of safety data - oldest IV iron preparation 9
Limitations:
- Lower maximum single dose (200 mg) compared to newer agents like ferric carboxymaltose (1000 mg) 1
- Requires multiple visits for complete iron repletion (typically 5-10 doses) 1
- More expensive than oral iron but cost-effective given superior efficacy 1, 11